Tectonic Therapeutic (TECX) said late Thursday that its lead asset TX45 for the potential treatment of group 2 pulmonary hypertension in heart failure with preserved ejection fraction showed "minimal" adverse events in a phase 1a clinical trial.
TX45 was well-tolerated and showed a "favorable" pharmacokinetic and pharmacodynamic relationship that was used to identify doses for phase 2 clinical trial, the company said.
"These topline phase 1a findings for TX45 validate the preliminary data previously presented at lower doses, and we look forward to sharing the full trial results at the AHA Scientific Sessions later this year," Tectonic Chief Executive Alise Reicin said.
Price: 19.81, Change: +0.01, Percent Change: +0.05
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。